aHUS Trial Watch 14
A trial has been designed by Alexion to examine the efficacy of Ravulizumab to treat those with a Thrombotic Microngiopathy ,…
Atypical HUS Research: What’s New OCT 2021
We marked aHUS Awareness Day (24 Sept) with our own advocacy-based research, releasing the 1st report of data and insights from…
Spotlight on aHUS Research – July 2021
Atypical HUS Research - What's New? The aHUS Alliance Global Action team has created a virtual 'library' of publications that are aHUS-specific and are categorized by topics such as diagnosis, treatment, genetics, thrombotic microangiopathy (TMA), complement, transplant, pregnancy, and more.
aHUS Research Update: Dec 2020
What's new in atypical HUS Research & Publications? aHUS Alliance Global Action - Keeping you updated with new aHUS research as of December 2020.
Atypical HUS Key Facts & Info – 2020 Sept 2021
Article No. 377 16 September 2020 Atypical HUS: Key Facts & Info Atypical Hemolytic Uremic Syndrome - an ultra…
2020 Atypical Drug Discovery Review, released by the aHUS Alliance
2020 overview of atypical HUS therapeutic drug development, by the aHUS Alliance
2019 Atypical HUS Fact Sheets
Atypical HUS: Fact Sheets & Research (2019 - SEPT - 2020 Edition) The aHUS Alliance provides informational resources about this rare disease for aHUS families & advocates around the world. Highlight boxes of aHUS research from the past year are provided in the full version, Key Facts and Research. The 'aHUS: In Brief 2019' version is a single page of aHUS facts to Print & Share.
OMS721: Omeros Research Collaboration with University of Cambridge
Pharma News: an Atypical HUS update from the aHUS Alliance. In its 11 December 2018 press release, the Omeros Corporation announced a new collaboration with a UK university to create the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). Focus of the OC3IR will be research into OMS721 and OMS906, but how will it engage other aHUS stakeholders interested in OMS721 clinical trials and atypical HUS advancements in research?
Breaking Down Barriers in aHUS Clinical Trials
Break down in communication flows and fragmented outreach have built barriers for research and clinical trial enrollment regarding advancing new options for those with the rare disease atypical HUS (aHUS, or hemolytic uremic syndrome). The aHUS Alliance looks at current challenges, and potential pathways to explore and engage.